Terri L. Cain

Terri L. Cain

Auto-generated profile, based on publicly available information

Terri L. Cain

Department of Haematology, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2024 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
TCTerri L. Cain
Terri L. Cain
MDMarta Derecka
Marta Derecka
SMShannon McKinney-Freeman
Shannon McKinney-Freeman

26 September 2024 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
TCTerri L. Cain
Terri L. Cain
MDMarta Derecka
Marta Derecka
SMShannon McKinney-Freeman
Shannon McKinney-Freeman

22 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
ABAditya Barve
Aditya Barve
PDPreeti Dabas
Preeti Dabas
ACAdam Cornwell
Adam Cornwell
PSPramika Sriram
Pramika Sriram
AKAlex Kopyov
Alex Kopyov
SMShannon McKinney-Freeman
Shannon McKinney-Freeman
Sickle cell disease (SCD) is a blood disorder affecting millions worldwide. Emerging evidence reveals that SCD pathophysiology increases the risk of myeloid malignancies and hematopoietic stem cell (HSC) dysfunction, likely because of chronic stress on bone marrow. To investigate this further, we interrogated bone marrow hematopoietic stem and progenitor cells (HSPCs) from mice and individuals with SCD and observed molecular signatures of chronic cellular stress including oxidative stress, DNA damage, and hallmarks of senescence. Consistent with these findings, SCD HSPCs displayed transcriptomic dysregulation of senescence-associated molecular programs and diminished mitogen response with prolonged cell cycle kinetics during time-lapse live cell imaging. SCD mice displayed a marked loss of immunophenotypic bone marrow HSPCs by flow cytometry and functional blood repopulating HSPCs in transplantation studies, whereas human SCD bone marrow HSPCs exhibited poor ex vivo hematopoietic colony-forming ability, and these phenotypes were reversed after senescence-targeting therapy with either ABT-263 (navitoclax) or the combination of dasatinib and quercetin. Thus, treatment with senescence-targeting therapy improves bone marrow HSPC function in vivo in mice and ex vivo in cells from individuals with SCD and could represent a possible strategy to improve HSPC health, promote manufacture of high-quality bespoke clinical products, and potentially enhance the safety of potentially curative gene therapies using autologous HSPCs from individuals with SCD.

30 March 2026 in Experimental Hematology
Verified
Journal Article
Closed access
ABAditya Barve
Aditya Barve
PDPreeti Dabas
Preeti Dabas
TCTerri Cain
Terri Cain
SMShannon McKinney-Freeman
Shannon McKinney-Freeman